People · Operator
Named in public records as an officer, director or promoter · active 2019–2019 · Biotech / Pharma, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Generian Pharmaceuticals, Inc. | — | Biotech / Pharma | Series A | $13.0M | $435.2M | 2019 |
| Ariel Precision Medicine, Inc. | — | Biotechnology | Series A | $5.4M | $190.5M | 2019 |
Hank Safferstein at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Hank Safferstein on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Smith | 1 | 42 |
| John Moore | 1 | 12 |
| Jeanne Cunicelli | 1 | 7 |
| Mary Del Brady | 1 | 4 |
| Stephan Dietrich | 1 | 4 |
| Matthias Kleinz | 1 | 2 |
| David Whitcomb | 1 | 1 |
| Jessica Gibson | 1 | 1 |
| Beibei Chen | 1 | 1 |
| Toren Finkel | 1 | 1 |
| David T.B. Whitcomb | 1 | 1 |
| Christopher T.B. Moehle | 1 | 1 |
| David T.B. Smith | 1 | 1 |
| John T.B. Moore | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.